0
Your cart

Your cart is empty

Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries

Buy Now

Risk-sharing in the Pharmaceutical Industry - The Case of Out-licensing (Paperback, 2006 ed.) Loot Price: R3,127
Discovery Miles 31 270
Risk-sharing in the Pharmaceutical Industry - The Case of Out-licensing (Paperback, 2006 ed.): Gerrit Reepmeyer

Risk-sharing in the Pharmaceutical Industry - The Case of Out-licensing (Paperback, 2006 ed.)

Gerrit Reepmeyer

Series: Contributions to Management Science

 (sign in to rate)
Loot Price R3,127 Discovery Miles 31 270 | Repayment Terms: R293 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year."

General

Imprint: Physica-Verlag
Country of origin: Germany
Series: Contributions to Management Science
Release date: December 2005
First published: 2006
Authors: Gerrit Reepmeyer
Dimensions: 235 x 155 x 16mm (L x W x T)
Format: Paperback
Pages: 297
Edition: 2006 ed.
ISBN-13: 978-3-7908-1667-9
Categories: Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries
LSN: 3-7908-1667-1
Barcode: 9783790816679

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

You might also like..

Empire Of Pain - The Secret History of…
Patrick Radden Keefe Paperback R385 R349 Discovery Miles 3 490
Pharmacology In Clinical Practice…
Gustav Schellack Paperback R507 Discovery Miles 5 070
EU Competition Law and Pharmaceuticals
Wolf Sauter, Marcel Canoy, … Hardcover R3,704 Discovery Miles 37 040
Death in Mud Lick - A Coal Country Fight…
Eric Eyre Paperback R490 R456 Discovery Miles 4 560
The Hard Sell - Crime and Punishment at…
Evan Hughes Paperback R299 R271 Discovery Miles 2 710
The Commercialization of Pharmaceutical…
James Hou Hardcover R3,176 Discovery Miles 31 760
Vaccine Development - From Concept to…
A. Krishna Prasad Hardcover R5,590 Discovery Miles 55 900
Opioids for the Masses - Big Pharma's…
Trey Garrison, Richard Mcclure Hardcover R996 Discovery Miles 9 960
Industrial Pharmacy
Ajay Semalty Hardcover R1,843 Discovery Miles 18 430
DEO's Financial Secrets to Grow Dental…
Ken Kaufman, Ashley Kaufman Hardcover R958 R831 Discovery Miles 8 310
Memoirs of a Modern Medicine Man
Frederick W Heyl Hardcover R1,342 Discovery Miles 13 420
Pharmaceutical Engineering
Dulal Krishna Tripathi, Nirmalya Tripathi Hardcover R1,768 Discovery Miles 17 680

See more

Partners